Cutaneous allodynia as predictor for treatment response in chronic migraine: a cohort study

[1]  D. Borsook,et al.  Pre-treatment non-ictal cephalic allodynia identifies responders to prophylactic treatment of chronic and episodic migraine patients with galcanezumab: A prospective quantitative sensory testing study (NCT04271202) , 2023, Cephalalgia : an international journal of headache.

[2]  M. Filippi,et al.  Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients , 2022, The Journal of Headache and Pain.

[3]  P. Pozo‐Rosich,et al.  Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months , 2021, The Journal of Headache and Pain.

[4]  S. Bottiroli,et al.  Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study , 2021, The Journal of Headache and Pain.

[5]  R. Lipton,et al.  Efficacy of erenumab in chronic migraine patients with and without ictal allodynia , 2021, Cephalalgia : an international journal of headache.

[6]  R. Lipton,et al.  Pathophysiology, prevention, and treatment of medication overuse headache , 2019, The Lancet Neurology.

[7]  S. Sacco,et al.  Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention , 2019, The Journal of Headache and Pain.

[8]  H. Diener,et al.  Erenumab in chronic migraine with medication overuse , 2019, Neurology.

[9]  A. Rapoport,et al.  The American Headache Society’s Position Statement on Integrating New Migraine Treatments into Clinical Practice – Comments , 2019, Headache.

[10]  M. Ferrari,et al.  Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial , 2019, Brain : a journal of neurology.

[11]  P. Goadsby,et al.  Nitroglycerine triggers triptan-responsive cranial allodynia and trigeminal neuronal hypersensitivity , 2018, Brain : a journal of neurology.

[12]  R. De Icco,et al.  Dissecting out migraine complexity through comprehensive analysis of allodynia. , 2018, Brain : a journal of neurology.

[13]  S. Bottiroli,et al.  Psychological, clinical, and therapeutic predictors of the outcome of detoxification in a large clinical population of medication-overuse headache: A six-month follow-up of the COMOESTAS Project , 2018, Cephalalgia : an international journal of headache.

[14]  J. Olesen.  International Classification of Headache Disorders , 2018, The Lancet Neurology.

[15]  C. Lundqvist,et al.  Predictors of successful primary care detoxification treatment for medication‐overuse headache , 2017, Acta neurologica Scandinavica.

[16]  Philip R Holland,et al.  Pathophysiology of Migraine: A Disorder of Sensory Processing. , 2017, Physiological reviews.

[17]  Kirk W. Johnson,et al.  The role of calcitonin gene–related peptide in peripheral and central pain mechanisms including migraine , 2017, Pain.

[18]  A. May,et al.  Chronic migraine: risk factors, mechanisms and treatment , 2016, Nature Reviews Neurology.

[19]  M. Louter,et al.  Detoxification in medication-overuse headache, a retrospective controlled follow-up study: Does care by a headache nurse lead to cure? , 2016, Cephalalgia : an international journal of headache.

[20]  Loren J. Martin,et al.  Different immune cells mediate mechanical pain hypersensitivity in male and female mice , 2015, Nature Neuroscience.

[21]  T. Schwedt,et al.  Low heat pain thresholds in migraineurs between attacks , 2015, Cephalalgia : an international journal of headache.

[22]  M. Ferrari,et al.  Migraine pathophysiology: lessons from mouse models and human genetics , 2015, The Lancet Neurology.

[23]  T. Jensen,et al.  Allodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms , 2014, The Lancet Neurology.

[24]  D. Dodick,et al.  Increased susceptibility to cortical spreading depression in an animal model of medication-overuse headache , 2014, Cephalalgia : an international journal of headache.

[25]  M. Ferrari,et al.  Allodynia is associated with a higher prevalence of depression in migraine patients , 2014, Cephalalgia : an international journal of headache.

[26]  M. Ferrari,et al.  Cutaneous allodynia as a predictor of migraine chronification. , 2013, Brain : a journal of neurology.

[27]  L. Bendtsen,et al.  Modulation of central sensitisation by detoxification in MOH: Results of a 12-month detoxification study , 2013, Cephalalgia : an international journal of headache.

[28]  Wenqin Luo,et al.  The Functional Organization of Cutaneous Low-Threshold Mechanosensory Neurons , 2011, Cell.

[29]  L. Becerra,et al.  Thalamic sensitization transforms localized pain into widespread allodynia , 2010, Annals of neurology.

[30]  D. Dodick,et al.  Triptan‐induced latent sensitization: A possible basis for medication overuse headache , 2009, Annals of neurology.

[31]  R. Lipton,et al.  Prevalence and characteristics of allodynia in headache sufferers , 2008, Neurology.

[32]  R. Lipton,et al.  Cutaneous allodynia in the migraine population , 2008, Annals of neurology.

[33]  R. Cady,et al.  Symptoms of Cutaneous Sensitivity Pre-Treatment and Post-Treatment: Results from the Rizatriptan TAME Studies , 2007, Cephalalgia : an international journal of headache.

[34]  S. Silberstein,et al.  Can allodynic migraine patients be identified interictally using a questionnaire? , 2005, Neurology.

[35]  R. Burstein,et al.  Terminating Migraine With Allodynia and Ongoing Central Sensitization Using Parenteral Administration of COX1/COX2 Inhibitors , 2005, Headache.

[36]  R. Burstein,et al.  Defeating migraine pain with triptans: A race against the development of cutaneous allodynia , 2004, Annals of neurology.

[37]  Jes Olesen,et al.  The International Classification of Headache Disorders: 2nd edition. , 2004, Cephalalgia : an international journal of headache.

[38]  H. Fields,et al.  Peptidergic Nociceptors of Both Trigeminal and Dorsal Root Ganglia Express Serotonin 1D Receptors: Implications for the Selective Antimigraine Action of Triptans , 2003, The Journal of Neuroscience.

[39]  T. T. Haug,et al.  The validity of the Hospital Anxiety and Depression Scale. An updated literature review. , 2002, Journal of psychosomatic research.

[40]  D. Yarnitsky,et al.  An association between migraine and cutaneous allodynia , 2000, Annals of neurology.

[41]  M. Arnold.  Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition , 2018, Cephalalgia : an international journal of headache.

[42]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..